TTAB Overturns Rejection Of Eli Lilly Diabetes Product Mark
The Trademark Trial and Appeal Board has ruled that Eli Lilly and Co. can register a term for a branded diabetes treatment, saying a U.S. Patent and Trademark Office examiner was...To view the full article, register now.
Already a subscriber? Click here to view full article